Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...

A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...

Alpha2-adrenergic receptor agonists didn't get critically ill patients off the ventilator quicker than propofol in the head-to-head A2B trial. Median time from randomization to successful extubation ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

Share on Pinterest A recent study used computational methods to identify novel compounds that activate receptors involved in pain modulation without sedation. Peter Dazeley/Getty Images Research on ...

First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing ...